secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001558370-25-000150
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo
--------------------------------------------------------------------------------

- 19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.
- Placebo group (n=7) had 0% achieving IGA 0/1 or EASI 75.
- No significant safety issues; all 10 Cohort 2 patients completed 28-day full 200 mg once-daily dose.
- Cohort 2 fully enrolled (N=16); full results from all four cohorts expected Q2 2025.
- Soquelitinib 200 mg twice-daily dose being studied in Phase 3 for peripheral T cell lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000155837025000150/0001558370-25-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000155837025000150/crvs-20250113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer